Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results
“The current coronavirus pandemic is highlighting the critical importance of a deeper understanding of the immune response to disease broadly, making Adaptive’s technology more relevant than ever,” said
- Revenue was
$21.0 millionfor the quarter ended June 30, 2020, representing a 5% decrease from the second quarter in the prior year.
- Clinical sequencing volume increased 31% to 3,136 clinical tests delivered in the second quarter of 2020 compared to the second quarter 2019.
- Advanced our first immunoSEQ Dx clinical product in development for SARS-CoV-2 based on favorable results from a head-to-head study comparing Adaptive’s clinical T-cell based diagnostic test to two leading serology tests with additional publication forthcoming.
- Launched a new research product, immunoSEQ T-MAP™ COVID, to offer vaccine developers a tool to accurately and reproducibly measure the T-cell immune response to vaccines in development and track the persistence of that response over time.
- Received clearance from the
U.S. Food and Drug Administration(FDA) for clonoSEQ® Assay to detect and monitor minimal residual disease (MRD) in blood or bone marrow from patients with chronic lymphocytic leukemia (CLL).
- Initiated two clinical validation studies for immunoSEQ Dx®: ImmuneSENSE Lyme for Lyme disease, and ImmuneRACE to collect blood samples from people who have been exposed, are actively fighting or have recently recovered from COVID-19.
- Strengthened balance sheet with the successful completion of underwritten public offering, raising approximately
$271.7million in net proceeds.
Second Quarter 2020 Financial Results
Operating expenses were
Net loss was
Adjusted EBITDA (non-GAAP) was a loss of
Cash, cash equivalents and marketable securities was
2020 Financial Guidance
Adaptive Biotechnologies is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19.
Webcast and Conference Call Information
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the
Use of Non-GAAP Financial Measure
This press release includes references to Adjusted EBITDA, which is a non-GAAP financial measure that we define as net loss adjusted for interest and other income, net, income tax benefit (expense), depreciation and amortization and share-based compensation expenses. We have provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.
Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.
Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation, or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:
- all expenditures or future requirements for capital expenditures or contractual commitments;
- changes in our working capital needs;
- income tax benefit (expense), which may be a necessary element of our costs and ability to operate;
- the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;
- the non-cash component of employee compensation expense; and
- the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations.
In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.
Condensed Statements of Operations
(in thousands, except share and per share amounts)
|Three Months Ended
||Six Months Ended
|Cost of revenue||4,912||5,734||10,255||10,722|
|Research and development||25,992||16,527||49,927||29,010|
|Sales and marketing||14,332||8,897||28,339||16,714|
|General and administrative||12,238||6,662||24,059||13,666|
|Amortization of intangible assets||423||423||847||842|
|Total operating expenses||57,897||38,243||113,427||70,954|
|Loss from operations||(36,909||)||(16,105||)||(71,529||)||(36,150||)|
|Interest and other income, net||1,893||446||4,787||2,105|
|Income tax benefit||1,481||—||1,804||—|
|Fair value adjustment to Series E-1 convertible preferred
|Net loss attributable to common shareholders||$||(33,535||)||$||(16,369||)||$||(64,938||)||$||(35,009||)|
|Net loss per share attributable to common shareholders,
basic and diluted
|Weighted-average shares used in computing net loss per
share attributable to common shareholders, basic and
Condensed Balance Sheets
(in thousands, except share and per share amounts)
|Cash and cash equivalents||$||365,440||$||96,576|
|Short-term marketable securities (amortized cost of
|Accounts receivable, net||7,914||12,676|
|Prepaid expenses and other current assets||10,691||14,079|
|Total current assets||599,521||612,690|
|Property and equipment, net||26,833||60,355|
|Operating lease right-of-use assets||37,619||—|
|Long-term marketable securities (amortized cost of
|Intangible assets, net||11,081||11,928|
|Liabilities and shareholders’ equity|
|Accrued compensation and benefits||5,976||8,124|
|Current portion of deferred rent||—||371|
|Current operating lease liabilities||3,229||—|
|Current deferred revenue||75,699||60,994|
|Total current liabilities||93,422||78,313|
|Deferred rent liability, less current portion||—||6,918|
|Operating lease liabilities, less current portion||42,503||—|
|Deferred revenue, less current portion||187,462||219,332|
|Other long-term liabilities||1,496||93|
|Commitments and contingencies|
|Additional paid-in capital||958,097||935,834|
|Accumulated other comprehensive gain||2,153||671|
|Total shareholders’ equity||529,939||571,039|
|Total liabilities and shareholders’ equity||$||854,822||$||912,302|
The following table sets forth a reconciliation between our Adjusted EBITDA and our net loss, the most directly comparable GAAP financial measure, for each of the periods presented (in thousands):
|Three Months Ended
||Six Months Ended
|Interest and other income, net||(1,893||)||(446||)||(4,787||)||(2,105||)|
|Income tax benefit||(1,481||)||—||(1,804||)||—|
|Depreciation and amortization expense||1,998||1,870||3,976||3,653|
|Share-based compensation expense||6,373||3,332||11,048||6,378|
Source: Adaptive Biotechnologies